



# ESU-ESOU Masterclass on Non-Muscle-Invasive Bladder Cancer

www.esunmibc.org

VIRTUAL

4-5 February 2021

esou eaj esu European  
School of  
Urology

*Time zone: Central European Time (CET)*

## 13.00 Introduction

### Goals of the course

M. Babjuk, Prague (CZ), J. Palou, Barcelona (ES), M. Roupret, Paris (FR)

## MODULE 1: Pathology and diagnostic strategy

Panel: M. Roupret, Paris (FR) F. Liedberg, Lund (SE), A. Brisuda, Prague (CZ)

### 13.10 Pathology and molecular classification of bladder cancer, can it influence treatment decisions?

F. Liedberg, Lund (SE)

### 13.25 Q&A

F. Liedberg, Lund (SE)

### 13.30 Work-up in patients with gross haematuria, urinary cytology and markers. What do we really have to do?

A. Brisuda, Prague (CZ)

### 13.45 Q&A

A. Brisuda, Prague (CZ)

## MODULE 2: Endoscopic management

Panel: J. Palou, Barcelona (ES), M. Babjuk, Prague (CZ), B. Malavaud, Toulouse (FR), A. Breda, Barcelona (ES)

### 13.50 Strategy and technique of TURB – indications, surgical strategy, available equipment

M. Babjuk, Prague (CZ)

### 14.05 Q&A

M. Babjuk, Prague (CZ)

### 14.10 Methods of advanced tumour visualization, how to use them in daily practice?

B. Malavaud, Toulouse (FR)

### 14.25 Q&A

B. Malavaud, Toulouse (FR)

### 14.30 Lasers in NMIBC surgery

A. Breda, Barcelona (ES)

### 14.40 Q&A

A. Breda, Barcelona (ES)

## Videos “How I do ...”

Panel: J. Palou, Barcelona (ES), M. Babjuk, Prague (CZ), B. Malavaud, Toulouse (FR), A. Breda, Barcelona (ES), L. Lusuardi, Salzburg (AT), F. Witjes, Nijmegen (NL)

### 14.45 Standard TURB with PDD

F. Witjes, Nijmegen (NL)

### 15.00 En-bloc resection with NBI

B. Malavaud, Toulouse (FR)

### 15.15 En-bloc resection with ImageS

L. Lusuardi, Salzburg (AT)

**15.30 En-bloc resection with incision electrode**

M. Babjuk, Prague (CZ)

**15.45 En-bloc resection with Superthulium laser**

A. Breda, Barcelona (ES)

**16.00 Discussion**

**How to manage difficult situations during TURB?**

Panel: M. Babjuk, Prague (CZ), M. Roupret, Paris (FR), J. Palou, Barcelona (ES)

**16.20 How to manage difficult bleeding? Is TUR syndrome a problem?**

M. Roupret, Paris (FR)

**16.35 Q&A**

M. Roupret, Paris (FR)

**16.40 How to prevent obturator jerk? Intra and extraperitoneal perforation, how to prevent that and what to do?**

J. Palou, Barcelona (ES)

**16.55 Q&A**

J. Palou, Barcelona (ES)

**17.00 End of day, farewell virtual toast**

**FRIDAY 5 FEBRUARY**

**MODULE 3: Some more videos: TURB in difficult situations**

Panel: M. Roupret Paris (FR), M. Babjuk, Prague (CZ), B. Malavaud, Toulouse (FR),

L. Lusuardi, Salzburg (AT)

**08.00 Tumor in the diverticulum**

B. Malavaud, Toulouse (FR)

**08.15 Ureteric ostium involvement**

M. Babjuk, Prague (CZ)

**08.45 Anterior bladder wall and dome of the bladder**

L. Lusuardi, Salzburg (AT)

**MODULE 4: Risk stratification and risk adjusted management**

Panel: M. Babjuk, Prague (CZ), J. Palou, Barcelona (ES), F. Witjes, Nijmegen (NL),

A. Breda, Barcelona (ES)

**09.00 Risk stratification and tailored intravesical management according to the EAU guidelines**

J. Palou, Barcelona (ES)

**09.15 Q&A**

J. Palou, Barcelona (ES)

**09.20 Intravesical treatment in NMIBC, how to exhaust and improve the efficacy? Intravesical chemo, BCG, EMDA, SYNERGO, HIVEC and UNITHERMIA**

F. Witjes, Nijmegen (NL)

**09.45 Q&A**

F. Witjes, Nijmegen (NL)

**09.50 Complications of intravesical treatment and their management**

A. Breda, Barcelona (ES)

**10.05 Q&A**

A. Breda, Barcelona (ES)

## **MODULE 5: Management of patients with BCG failure**

Panel: J. Palou, Barcelona (ES), M. Roupret, Paris (FR), F. Witjes, Nijmegen (NL),  
S. Shariat, Vienna (AT)

### **10.10 Definition of BCG failure, current and perspective treatment options**

M. Roupret, Paris (FR)

### **10.35 Q&A**

M. Roupret, Paris (FR)

### **10.40 Radical cystectomy for NMIBC: What has to be done, extent, diversion?**

F. Witjes, Nijmegen (NL)

### **10.55 Q&A**

F. Witjes, Nijmegen (NL)

### **11.00 Where is the future in the treatment of NMIBC? What is in the pipeline and may be expected in the near future?**

S. Shariat, Vienna (AT)

### **11.15 Q&A**

A. Breda, Barcelona (ES)

### **11.20 3 cases prepared by participants discussed by the faculty**

Panel: J. Palou, Barcelona (ES), M. Roupret, Paris (FR), M. Babjuk, Prague (CZ),  
F. Liedberg (SE)

### **12.00 Closing remarks and farewell virtual toast**

M. Babjuk, Prague (CZ), J. Palou, Barcelona (ES), M. Roupret, Paris (FR)

## **Faculty**

M. Babjuk, Prague (CZ)

A. Breda, Barcelona (ES)

A. Brisuda, Prague (CZ)

F. Liedberg, Lund (SE)

L. Lusuardi, Salzburg (AT)

B. Malavaud, Toulouse (FR)

J. Palou, Barcelona (ES)

M. Roupret, Paris (FR)

S. Shariat, Vienna (AT)

F. Witjes, Nijmegen (NL)